vs
Side-by-side financial comparison of AtriCure, Inc. (ATRC) and High Tide Inc. (HITI). Click either name above to swap in a different company.
High Tide Inc. is the larger business by last-quarter revenue ($142.5M vs $141.2M, roughly 1.0× AtriCure, Inc.). AtriCure, Inc. runs the higher net margin — 0.1% vs -1.9%, a 2.0% gap on every dollar of revenue.
AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.
High Tide Inc. is a Canada-based consumer retail and lifestyle company focused on the global cannabis sector. It operates a large network of licensed cannabis dispensaries across North America, sells cannabis consumption accessories and branded cannabis products, and runs multiple leading e-commerce platforms catering to recreational and medical cannabis users.
ATRC vs HITI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $141.2M | $142.5M |
| Net Profit | $108.0K | $-2.7M |
| Gross Margin | 77.4% | — |
| Operating Margin | 23.0% | 0.0% |
| Net Margin | 0.1% | -1.9% |
| Revenue YoY | 14.3% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $141.2M | $142.5M | ||
| Q4 25 | $140.5M | — | ||
| Q3 25 | $134.3M | $131.7M | ||
| Q2 25 | $136.1M | $124.3M | ||
| Q1 25 | $123.6M | — | ||
| Q4 24 | $124.3M | $128.1M | ||
| Q3 24 | $115.9M | — | ||
| Q2 24 | $116.3M | — |
| Q1 26 | $108.0K | $-2.7M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-267.0K | $991.0K | ||
| Q2 25 | $-6.2M | $166.0K | ||
| Q1 25 | $-6.7M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.9M | — | ||
| Q2 24 | $-8.0M | — |
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | — | ||
| Q3 25 | 75.5% | 26.9% | ||
| Q2 25 | 74.5% | 28.4% | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.5% | 28.1% | ||
| Q3 24 | 74.9% | — | ||
| Q2 24 | 74.7% | — |
| Q1 26 | 23.0% | 0.0% | ||
| Q4 25 | 1.8% | — | ||
| Q3 25 | 0.2% | 2.3% | ||
| Q2 25 | -4.5% | 1.6% | ||
| Q1 25 | -4.8% | — | ||
| Q4 24 | -11.7% | 2.2% | ||
| Q3 24 | -6.4% | — | ||
| Q2 24 | -6.2% | — |
| Q1 26 | 0.1% | -1.9% | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.2% | 0.8% | ||
| Q2 25 | -4.5% | 0.1% | ||
| Q1 25 | -5.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.8% | — | ||
| Q2 24 | -6.9% | — |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.01 | — | ||
| Q2 25 | $-0.13 | — | ||
| Q1 25 | $-0.14 | — | ||
| Q4 24 | $-0.33 | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $146.2M | — |
| Total DebtLower is stronger | $61.0M | — |
| Stockholders' EquityBook value | $491.7M | — |
| Total Assets | $644.0M | — |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | — | ||
| Q3 25 | $147.9M | — | ||
| Q2 25 | $117.8M | — | ||
| Q1 25 | $99.9M | — | ||
| Q4 24 | $122.7M | — | ||
| Q3 24 | $130.3M | — | ||
| Q2 24 | $114.0M | — |
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — |
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | — | ||
| Q3 25 | $476.5M | — | ||
| Q2 25 | $464.5M | — | ||
| Q1 25 | $454.6M | — | ||
| Q4 24 | $461.0M | — | ||
| Q3 24 | $465.0M | — | ||
| Q2 24 | $462.1M | — |
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | — | ||
| Q3 25 | $635.4M | — | ||
| Q2 25 | $608.8M | — | ||
| Q1 25 | $591.6M | — | ||
| Q4 24 | $609.3M | — | ||
| Q3 24 | $615.1M | — | ||
| Q2 24 | $597.3M | — |
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
HITI
Segment breakdown not available.
